These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Assessing the post hoc effectiveness of tixagevimab-cilgavimab for prevention of SARS-CoV-2 infections in solid organ transplant recipients. Jordan SC; Joung SY; Wang M; Tran TA; Bravo M; Masoom H; Chang C; Mendez M; Sun N; Patel J; Kittleson M; Frias E; Prostko JC; Ebinger JE; Cheng S; Sobhani K Transpl Infect Dis; 2024 Feb; 26(1):e14182. PubMed ID: 37885435 [TBL] [Abstract][Full Text] [Related]
5. A single-center review of pre-exposure prophylaxis with tixagevimab-cilgavimab in solid organ transplant recipients. Morado F; Davoudi R; Kawewat-Ho P; Nanda N; Cartus R; Shaikh SA Transpl Infect Dis; 2023 Aug; 25(4):e14086. PubMed ID: 37314092 [TBL] [Abstract][Full Text] [Related]
6. The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab-Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center. Al-Obaidi MM; Gungor AB; Kurtin SE; Mathias AE; Tanriover B; Zangeneh TT Am J Med; 2023 Jan; 136(1):96-99. PubMed ID: 36181789 [TBL] [Abstract][Full Text] [Related]
7. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916 [TBL] [Abstract][Full Text] [Related]
8. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis. Khorramnia S; Navidi Z; Orandi A; Iravani MM; Orandi A; Malekabad ES; Moghadam SHP Clin Transplant Res; 2024 Jun; 38(2):136-144. PubMed ID: 38904088 [TBL] [Abstract][Full Text] [Related]
9. Tixagevimab/cilgavimab for the prevention of COVID-19 in solid organ transplant recipients. Eribes E; Votruba C; Tinkham T; Huang A; Ilges D; Kunze K; Hudson M Clin Transplant; 2024 Feb; 38(2):e15261. PubMed ID: 38375915 [TBL] [Abstract][Full Text] [Related]
10. Evolving impact of the COVID-19 pandemic on lung transplant recipients: A single-center experience. Sindu D; Razia D; Bay C; Padiyar J; Grief K; Buddhdev B; Arjuna A; Abdelrazek H; Mohamed H; McAnally K; Omar A; Walia R; Schaheen L; Tokman S J Heart Lung Transplant; 2024 Mar; 43(3):442-452. PubMed ID: 37852512 [TBL] [Abstract][Full Text] [Related]
11. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis. Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R Transpl Int; 2024; 37():12061. PubMed ID: 38328617 [TBL] [Abstract][Full Text] [Related]
12. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients. Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204 [No Abstract] [Full Text] [Related]
14. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients. Sanayei AM; Montalvan A; Faria I; Ochalla J; Pavlakis M; Blair BM; Alonso CD; Curry M; Saberi B Transplant Proc; 2023 Oct; 55(8):1784-1792. PubMed ID: 37661468 [TBL] [Abstract][Full Text] [Related]
15. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis. Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147 [TBL] [Abstract][Full Text] [Related]
16. Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients. Lombardi A; Viero G; Villa S; Biscarini S; Palomba E; Azzarà C; Iannotti N; Mariani B; Genovese C; Tomasello M; Tonizzo A; Fava M; Valzano AG; Morlacchi LC; Donato MF; Castellano G; Cassin R; Carrabba M; Muscatello A; Gori A; Bandera A Biomedicines; 2023 May; 11(6):. PubMed ID: 37371635 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era. Gottlieb J; Simon S; Barton J; Barnikel M; Bachmann M; Klingenberg MS; Veit T; Kneidinger N Infection; 2023 Oct; 51(5):1481-1489. PubMed ID: 36929650 [TBL] [Abstract][Full Text] [Related]
18. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak. You J; Tian J; Wu H; Kang W; Wen J; Xu H; Shi W; Wang Z; Wei H; Du Y; Li X; Mu G; Zhou M; Gu Z; Qu J Expert Rev Anti Infect Ther; 2023; 21(12):1365-1371. PubMed ID: 37855094 [TBL] [Abstract][Full Text] [Related]